Blood Product Development

The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.

IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry. With a mission to accelerate innovation for a healthier world and a vision to power smarter healthcare for everyone, everywhere, IQVIA leverages unparalleled data, transformative technology, and deep healthcare expertise to drive better patient outcomes. Operating in over 100 countries with approximately 88,000 employees, IQVIA supports pharmaceutical, biotech, medtech, public health, and government organizations with a comprehensive portfolio of services and solutions. The company is recognized for its Connected Intelligence™, healthcare-grade AI, and commitment to sustainability, innovation, and evidence-based insights that shape the future of healthcare globally. IQVIA is also dedicated to reducing health inequities and driving sustainable change through innovation, collaboration, and data-driven solutions, partnering with organizations worldwide to address complex healthcare challenges.

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Vascarta Inc. is a pharmaceutical company that has developed a patented topical/transdermal delivery platform aimed at improving the bioavailability of drugs, particularly curcumin, a compound known for its anti-inflammatory and antioxidant properties. The company focuses on addressing unmet medical needs through innovative formulations that enhance therapeutic efficacy and patient outcomes.

Stream Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class targeted therapeutics for acute neurotrauma and chronic neurodegenerative diseases. The company is dedicated to revolutionizing cerebrovascular repair and developing novel solutions for neurotrauma and neurodegeneration, including conditions such as stroke, traumatic brain injury, and Alzheimer's disease.

FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. The company focuses on purpose-driven innovation to empower healthcare professionals and enhance patient outcomes across various medical fields.

Qidni Labs is a NATO DIANA company recognized by Fast Company as a 2025 World Changing Idea. The company has developed a portable, nearly waterless hemodialysis system that will make treatment accessible for over 10 million patients every year.

VirTech Bio is an early-stage biotechnology company based in Natick, Massachusetts, focused on developing a human-derived hemoglobin-based oxygen carrier (HBOC) for use as a temporary blood substitute in trauma and transplantation. The company leverages expertise in hemoglobin polymerization to address critical needs in emergency medicine and organ preservation, with a pipeline also targeting veterinary and research applications. Process innovations allow scalable and contract-based manufacturing, supported by significant non-dilutive funding from the US Department of Defense and private investment.

GreenLifeTech has developed a safe, non-chemical means of removing oxygen from within a closed container operated at atmospheric pressure (no vacuum). This inert environment allows for the extending the shelf life of perishable material. Initially, the focus was on fresh produce which can have its shelf life extended by up to 3 - 5x, thereby reducing food waste and promoting healthier living. An EPA SBIR phase II contract has already been awarded for implementation of the technology in consumer refrigerators. In addition, the technology is applicable to preserving transfusion blood. NIH and US Army studies have already shown that storing blood in an anaerobic environment improves the quality and extends the shelf life of blood. The GreenLifeTech now makes this cost effective and applicable in the field.

Anavatos Bio is an early-stage biotechnology start-up based in Seattle, Washington, dedicated to revolutionizing biologics manufacturing. The company is driven by a team of experienced scientists, engineers, and entrepreneurs passionate about increasing access to protein therapeutics. Their mission is to enable faster, more efficient, and cost-effective production of biologics at smaller scales, supporting early-phase research and advancing a new medical paradigm that delivers greater value to patients.

Altra Inc. is at the forefront of revolutionizing infusion therapy with its innovative Altra Infusion System. The company is dedicated to addressing the critical challenges in the infusion industry, such as mechanical failures, flow issues, and false alarms, which contribute to a significant portion of medication errors and adverse drug events. Altra's mission is to ensure patient safety and improve healthcare delivery through advanced technology solutions.

MK Strategy Group is a certified Service-Disabled Veteran-Owned Small Business (SDVOSB) and a leading government contractor specializing in innovative healthcare solutions for military, government, and commercial sectors. With over two decades of experience, the company excels in medical procurement and facility development. MK Strategy Group bridges the gap between medical technology providers and government agencies, offering tailored, turnkey solutions that accelerate success in the government market. Their approach combines military precision, deep industry expertise, and a commitment to quality, innovation, and financial stability—enabling them to manage large-scale, complex projects with efficiency and reliability.

SanaHeal is dedicated to developing next-generation bioadhesive technologies inspired by nature to solve significant challenges in healthcare. Their innovative solutions are designed to adhere to wet and uneven surfaces, providing rapid and robust adhesion for various medical applications.

Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.